Litcius/Paper detail

Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial

Thomas Powles, Toni K. Choueiri, Laurence Albigès, Katriina Peltola, Guillermo de Velasco, Mauricio Burotto, Cristina Suárez, Pooja Ghatalia, Roberto Iacovelli, Elaine T. Lam, Elena Verzoni, Mahmut Gümüş, Walter M. Stadler, Christian Kollmannsberger, Bohuslav Melichar, Balaji Venugopal, M. Gross-Goupil, Alexandr Poprach, Maria De Santis, Mimma Rizzo, Reshma Shinde, Todd L. Saretsky, He Li, Rodolfo F. Perini, Donna Vickery, Brian I. Rini

2025The Lancet Oncology10 citationsDOI

Topics & Concepts

EverolimusOpen labelRenal cell carcinomaMedicineQuality of life (healthcare)Internal medicineOncologyHealth related quality of lifeUrologyRandomized controlled trialNursingDiseaseRenal cell carcinoma treatmentCancer, Hypoxia, and MetabolismCardiac tumors and thrombi
Health-related quality of life with belzutifan versus everolimus for advanced renal cell carcinoma (LITESPARK-005): patient-reported outcomes from a randomised, open-label, phase 3 trial | Litcius